P-121 Phase Ib trial of oxaliplatin, UGT1A1 genotype-directed dosing of irinotecan and chronomodulated capecitabine (OXIRI) chemotherapy in patients with advanced pancreatic cancer

Lignende værker

• UGT1A1 Genotype-guided Phase I Study of Irinotecan, Oxaliplatin, and Capecitabine
  af: Goetz, Matthew P., et al.
  Udgivet: (2013)
• Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine
  af: Krishnamurthi, Smitha S., et al.
  Udgivet: (2008)
• DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan
  af: Falvella, Felicia Stefania, et al.
  Udgivet: (2015)
• Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial
  af: Garufi, C, et al.
  Udgivet: (2010)
• A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients
  af: Garufi, C, et al.
  Udgivet: (2003)